Our Science
We leverage the adaptive immune responses to destroy cancerous cells
At Scancell, we use vaccines to induce immune responses or monoclonal antibodies to redirect immune cells or drugs. Through targeting modifications of proteins and lipids prevalent in cancer, we can generate potent anti-tumour responses by harnessing the adaptive immune response.
Vaccines
ImmunoBody®
ImmunoBody® DNA vaccines encode a protein in the form of a modified antibody, which is engineered to express epitopes from a cancer antigen whilst retaining the ability to target activated antigen presenting cells in vivo.
Moditope®
The Moditope® platform is a unique class of potent, off the shelf peptide vaccine targeting posttranslational modifications expressed by a wide range of tumours.
Antibodies
GlyMab®
High-affinity tumour specific monoclonal antibodies that target highly differentiated glycans that are preferentially expressed on tumours, making them attractive development candidates.
AvidiMab®
Enhancing the potency and efficacy of any clinical antibody or antibody-based product validated in the ImmunoBody® clinical product iSCIB1+.
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.
